Drug profile · INN
ziconotide acetate
PRIALT
ziconotide acetate (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker. Route of administration: intrathecal. Current US regulatory status: approved.
Drug details — ziconotide acetate
- US status
- approved
- Class
- —
- Route
- INTRATHECAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ziconotide acetate (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker. Route of administration: intrathecal. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-gated N-type calcium channel alpha-1B subunit blocker
Primary target: Voltage-dependent N-type calcium channel subunit alpha-1B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ziconotide acetate?
ziconotide acetate (PRIALT) is a voltage-gated n-type calcium channel alpha-1b subunit blocker. Route of administration: intrathecal. Current US regulatory status: approved.
What is the brand name for ziconotide acetate?
PRIALT is a marketed brand name for ziconotide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ziconotide acetate?
ziconotide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.